Table 3.
Prevalence of long-term remission from hyperprolactinemia after DA withdrawal: an overview of the literature
| Author, year (reference) | Patient no. | Therapy | Duration (mo) | Follow-up (mo) | Remission (%) | |||
|---|---|---|---|---|---|---|---|---|
| NTHP | Micro | Macro | Overall | |||||
| Johnston, 1984 (153) | 15 | BRC | 42 | 12 | NA | NA | NA | 7 |
| Zarate, 1983 (158) | 16 | BRC | 24 | 24 | — | 17 | 100 | 37.5 |
| Moriondo, 1985 (154) | 36 | BRC | 24 | 30 | — | 22 | — | 22 |
| Wang, 1987 (156) | 24 | BRC | 24 | 12-48 | 40 | 8.7 | 4.3 | 10 |
| Rasmussen, 1987 (155) | 75 | BRC | 24-65 | 6 | NA | NA | NA | 44 |
| van’t Verlaat, 1991 (157) | 12 | BRC | 36-84 | 12 | — | — | 9 | 9 |
| Passos, 2002 (159) | 131 | BRC | 48 | 42 | — | 26 | 16 | 20.6 |
| Remission from bromocriptine | 309 | 2/5 (40%) | 28/133 (21%) | 17/108 (15.7%) | 19.1 | |||
| Ferrari, 1992 (162) | 127 | CAB | 40-84 | 12 | 8.1 | 7 | 10 | 7.9 |
| Muratori, 1997 (163) | 26 | CAB | 12 | 38-60 | — | 19 | — | 19 |
| Cannavò, 1999 (164) | 37 | CAB | 24 | 12 | — | 15.4 | 9.1 | 13.5 |
| Colao, 2003 (165) | 175 | CAB | 48 | 24-60 | 76 | 70 | 64 | 68.5 |
| Colao, 2007 (166) | 194 | CAB | 36-45 | 48 | 74 | 66 | 47 | 60 |
| Kharlip, 2009 (167) | 46 | CAB | 52 | 52 | 25 | 48 | 45 | 45.6 |
| Sala, 2016 (168) | 74 | CAB | 66-79 | 12 | — | 56 | 50 | 54 |
| Espinosa-Cárdenas, 2020 (169) | 50 | CAB | 60 | 132-408 | — | 18.7 | 38.3 | 32 |
| Kim, 2021 (170) | 44 | CAB | 12-120 | 12-97 | — | 78.9 | 63.6 | 75 |
| Remission from cabergoline | 773 | 43/93 (46.2%) | 238/479 (49.7%) | 119/253 (47%) | 48.5 | |||
| Biswas, 2005 (171) | 89 | Both | 37 | 12 | — | 36 | — | 36 |
| Guitelman, 2006 (172) | 100 | Both | 24-60 | 60 | — | 20 | 3 | 15 |
| Huda, 2010 (195) | 40 | Both | 108 | 12 | — | 22.5 | — | 22.5 |
| Barber, 2011 (173) | 60 | Both | 90 | 3-36 | — | 36 | 7 | 28.3 |
| Anagnostis, 2012 (174) | 26 | Both | 79 | 24 | — | 60 | 50 | 57.7 |
| Teixeira, 2017 (175) | 50 | Both | 118 ± 85 | — | — | 78 | 44.4 | 72 |
| Total | 1447 | 45/98 (45.9%) | 381/853 (44.6%) | 145/423 (34.3%) | ||||
Abbreviations: BRC, bromocriptine; CAB, cabergoline; DA, dopamine agonist; NA, not available; NTHP, nontumoral hyperprolactinemia.